GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00109517 | Liver | NAFLD | negative regulation of endopeptidase activity | 42/1882 | 252/18723 | 7.29e-04 | 9.29e-03 | 42 |
GO:00104667 | Liver | NAFLD | negative regulation of peptidase activity | 43/1882 | 262/18723 | 8.76e-04 | 1.07e-02 | 43 |
GO:005254712 | Liver | Cirrhotic | regulation of peptidase activity | 185/4634 | 461/18723 | 1.32e-13 | 1.09e-11 | 185 |
GO:005254812 | Liver | Cirrhotic | regulation of endopeptidase activity | 172/4634 | 432/18723 | 2.12e-12 | 1.58e-10 | 172 |
GO:004586112 | Liver | Cirrhotic | negative regulation of proteolysis | 136/4634 | 351/18723 | 3.46e-09 | 1.42e-07 | 136 |
GO:005134612 | Liver | Cirrhotic | negative regulation of hydrolase activity | 139/4634 | 379/18723 | 1.24e-07 | 3.42e-06 | 139 |
GO:001095111 | Liver | Cirrhotic | negative regulation of endopeptidase activity | 98/4634 | 252/18723 | 4.19e-07 | 9.77e-06 | 98 |
GO:001046612 | Liver | Cirrhotic | negative regulation of peptidase activity | 100/4634 | 262/18723 | 8.90e-07 | 1.84e-05 | 100 |
GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
GO:004586122 | Liver | HCC | negative regulation of proteolysis | 186/7958 | 351/18723 | 4.19e-05 | 4.11e-04 | 186 |
GO:005134622 | Liver | HCC | negative regulation of hydrolase activity | 195/7958 | 379/18723 | 2.44e-04 | 1.82e-03 | 195 |
GO:001095121 | Liver | HCC | negative regulation of endopeptidase activity | 129/7958 | 252/18723 | 3.17e-03 | 1.47e-02 | 129 |
GO:001046621 | Liver | HCC | negative regulation of peptidase activity | 132/7958 | 262/18723 | 5.82e-03 | 2.42e-02 | 132 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITIH1 | SNV | Missense_Mutation | | c.1705N>G | p.Leu569Val | p.L569V | P19827 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
ITIH1 | SNV | Missense_Mutation | novel | c.1879C>T | p.Pro627Ser | p.P627S | P19827 | protein_coding | tolerated(0.1) | benign(0.057) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
ITIH1 | SNV | Missense_Mutation | rs148028644 | c.199N>A | p.Ala67Thr | p.A67T | P19827 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
ITIH1 | SNV | Missense_Mutation | rs777237459 | c.2016N>A | p.Asp672Glu | p.D672E | P19827 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
ITIH1 | SNV | Missense_Mutation | | c.663N>G | p.Ile221Met | p.I221M | P19827 | protein_coding | deleterious(0) | possibly_damaging(0.714) | TCGA-C8-A1HJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITIH1 | SNV | Missense_Mutation | | c.1916N>A | p.Pro639His | p.P639H | P19827 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
ITIH1 | SNV | Missense_Mutation | rs763101480 | c.1541G>A | p.Arg514His | p.R514H | P19827 | protein_coding | tolerated(0.06) | benign(0.189) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITIH1 | SNV | Missense_Mutation | novel | c.2156C>T | p.Ala719Val | p.A719V | P19827 | protein_coding | tolerated(0.28) | benign(0.1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITIH1 | SNV | Missense_Mutation | | c.1238N>A | p.Arg413His | p.R413H | P19827 | protein_coding | tolerated(0.55) | probably_damaging(0.915) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ITIH1 | SNV | Missense_Mutation | rs142551669 | c.2191N>A | p.Gly731Arg | p.G731R | P19827 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A6-6142-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD |